<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>7275001</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmid">32304022</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="pmc">7275001</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="publisher-id">287</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" pub-id-type="doi">10.1007/s11682-020-00287-6</article-id></all-ids><extracted-table><table-id>Tab1</table-id><table-label>Table 1</table-label><table-caption>Demographic and clinical characteristics of all subjects</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table 1</label><caption><p>Demographic and clinical characteristics of all subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left" colspan="2">Lung cancer (n = 18)</th><th align="left">HCs (n = 21)</th><th align="left"><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left">Age, year</td><td align="left" colspan="2">59.72 ± 9.04</td><td align="left">58.57 ± 9.61</td><td align="left">0.703<sup>a</sup></td></tr><tr><td align="left">Education, year</td><td align="left" colspan="2">10.59 ± 4.25</td><td align="left">10.71 ± 1.88</td><td align="left">0.904<sup>a</sup></td></tr><tr><td align="left">Gender, male/female</td><td align="left" colspan="2">13/5</td><td align="left">13/8</td><td align="left">0.828<sup>b</sup></td></tr><tr><td align="left" colspan="5">Histological diagnosis</td></tr><tr><td align="left"> Adenocarcinoma</td><td align="left" colspan="2">9(50)</td><td align="left"/><td align="left"/></tr><tr><td align="left"> Squamous cell carcinoma</td><td align="left" colspan="2">7 (39)</td><td align="left"/><td align="left"/></tr><tr><td align="left"> SCLC</td><td align="left" colspan="2">2 (11)</td><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="5">Tumor stage</td></tr><tr><td align="left"> Limited disease</td><td align="left" colspan="2">1 (5)</td><td align="left"/><td align="left"/></tr><tr><td align="left"> Extensive disease</td><td align="left" colspan="2">1 (5)</td><td align="left"/><td align="left"/></tr><tr><td align="left"> I</td><td align="left" colspan="2">3 (17)</td><td align="left"/><td align="left"/></tr><tr><td align="left"> II</td><td align="left" colspan="2">5(28)</td><td align="left"/><td align="left"/></tr><tr><td align="left"> III</td><td align="left" colspan="2">4 (22)</td><td align="left"/><td align="left"/></tr><tr><td align="left"> IV</td><td align="left" colspan="2">4 (22)</td><td align="left"/><td align="left"/></tr><tr><td align="left"/><td align="left">t0</td><td align="left">t1</td><td align="left"/><td align="left"/></tr><tr><td align="left">MMSE</td><td align="left">26.78 ± 1.17</td><td align="left">26.61 ± 1.19</td><td align="left">27.19 ± 1.03</td><td align="left">0.248<sup>a1</sup>;0.163<sup>a2</sup>;0.698<sup>a3</sup></td></tr><tr><td align="left">MoCA</td><td align="left">22.22 ± 1.93</td><td align="left">22.06 ± 2.94</td><td align="left">25.76 ± 1.61</td><td align="left">0.000<sup>*a1</sup>; 0.000<sup>*a2</sup>;0.817<sup>a3</sup></td></tr></tbody></table><table-wrap-foot><p>Data are expressed as Mean±SD, n (%) or median (range), <sup>a</sup>The P values are obtained by using two sample t-test; <sup>b</sup>The P values are obtained by using χ2 test. <sup>*</sup><italic>P</italic>&lt;0.05 is considered significant. <sup>a1</sup> The P value between lung cancer patients before chemotherapy and HCs;<sup>a2</sup> The P value between lung cancer patients after chemotherapy and HCs;<sup>a3</sup> The P value between lung cancer patients before and after chemotherapy. MMSE, Mini Mental State Exam; MoCA, Montreal Cognitive Assessment; HCs, healthy controls</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographic and clinical characteristics of all subjects</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left" colspan="2">Lung cancer (n = 18)</th><th align="left">HCs (n = 21)</th><th align="left">p value</th></tr></thead><tbody><tr><td align="left">Age, year</td><td align="left" colspan="2">59.72 ± 9.04</td><td align="left">58.57 ± 9.61</td><td align="left">0.703a</td></tr><tr><td align="left">Education, year</td><td align="left" colspan="2">10.59 ± 4.25</td><td align="left">10.71 ± 1.88</td><td align="left">0.904a</td></tr><tr><td align="left">Gender, male/female</td><td align="left" colspan="2">13/5</td><td align="left">13/8</td><td align="left">0.828b</td></tr><tr><td align="left" colspan="5">Histological diagnosis</td></tr><tr><td align="left"> Adenocarcinoma</td><td align="left" colspan="2">9(50)</td><td align="left"/><td align="left"/></tr><tr><td align="left"> Squamous cell carcinoma</td><td align="left" colspan="2">7 (39)</td><td align="left"/><td align="left"/></tr><tr><td align="left"> SCLC</td><td align="left" colspan="2">2 (11)</td><td align="left"/><td align="left"/></tr><tr><td align="left" colspan="5">Tumor stage</td></tr><tr><td align="left"> Limited disease</td><td align="left" colspan="2">1 (5)</td><td align="left"/><td align="left"/></tr><tr><td align="left"> Extensive disease</td><td align="left" colspan="2">1 (5)</td><td align="left"/><td align="left"/></tr><tr><td align="left"> I</td><td align="left" colspan="2">3 (17)</td><td align="left"/><td align="left"/></tr><tr><td align="left"> II</td><td align="left" colspan="2">5(28)</td><td align="left"/><td align="left"/></tr><tr><td align="left"> III</td><td align="left" colspan="2">4 (22)</td><td align="left"/><td align="left"/></tr><tr><td align="left"> IV</td><td align="left" colspan="2">4 (22)</td><td align="left"/><td align="left"/></tr><tr><td align="left"/><td align="left">t0</td><td align="left">t1</td><td align="left"/><td align="left"/></tr><tr><td align="left">MMSE</td><td align="left">26.78 ± 1.17</td><td align="left">26.61 ± 1.19</td><td align="left">27.19 ± 1.03</td><td align="left">0.248a1;0.163a2;0.698a3</td></tr><tr><td align="left">MoCA</td><td align="left">22.22 ± 1.93</td><td align="left">22.06 ± 2.94</td><td align="left">25.76 ± 1.61</td><td align="left">0.000*a1; 0.000*a2;0.817a3</td></tr></tbody></table></div>Data are expressed as Mean±SD, n (%) or median (range), aThe P values are obtained by using two sample t-test; bThe P values are obtained by using χ2 test. *P&lt;0.05 is considered significant. a1 The P value between lung cancer patients before chemotherapy and HCs;a2 The P value between lung cancer patients after chemotherapy and HCs;a3 The P value between lung cancer patients before and after chemotherapy. MMSE, Mini Mental State Exam; MoCA, Montreal Cognitive Assessment; HCs, healthy controls</transformed-table></extracted-table><extracted-table><table-id>Tab2</table-id><table-label>Table 2</table-label><table-caption>Abnormal static functional connectivity between groups</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table 2</label><caption><p>Abnormal static functional connectivity between groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">ROIs</th><th align="left">Group comparisons</th><th align="left">Brain region</th><th align="left">BA</th><th align="left">MNI Coordinates<break/>x, y, z (mm)</th><th align="left">T score</th><th align="left">Voxels</th></tr></thead><tbody><tr><td align="left">R-DLPFC</td><td align="left">t0 vs. HCs</td><td align="left">Temporal_Sup_L</td><td char="." align="char">81</td><td align="left">-48, -21, 3</td><td char="." align="char">-4.2286</td><td char="." align="char">89</td></tr><tr><td align="left"/><td align="left"/><td align="left">Parietal_Inf_L</td><td char="." align="char">61</td><td align="left">-54, -51,36</td><td char="." align="char">-5.8758</td><td char="." align="char">315</td></tr><tr><td align="left"/><td align="left">t1 vs. HCs</td><td align="left">Frontal_Sup_R</td><td char="." align="char">6</td><td align="left">24, 57, -6</td><td char="." align="char">-4.4452</td><td char="." align="char">109</td></tr><tr><td align="left"/><td align="left"/><td align="left">Frontal_Sup_L</td><td char="." align="char">5</td><td align="left">-15, 60, -9</td><td char="." align="char">-4.1401</td><td char="." align="char">52</td></tr><tr><td align="left"/><td align="left"/><td align="left">Frontal_Mid_L</td><td char="." align="char">7</td><td align="left">-39,30,42</td><td char="." align="char">-4.689</td><td char="." align="char">145</td></tr><tr><td align="left"/><td align="left"/><td align="left">Cingulum_Mid_R</td><td char="." align="char">34</td><td align="left">9, -21,33</td><td char="." align="char">-4.1414</td><td char="." align="char">65</td></tr><tr><td align="left"/><td align="left">t1 vs. t0</td><td align="left">Frontal_Sup_L</td><td char="." align="char">3</td><td align="left">-18, 45, 22</td><td char="." align="char">-4.5187</td><td char="." align="char">85</td></tr><tr><td align="left"/><td align="left"/><td align="left">Frontal_Mid_R</td><td char="." align="char">8</td><td align="left">45, 33, 51</td><td char="." align="char">-3.7625</td><td char="." align="char">45</td></tr><tr><td align="left">L-DLPFC</td><td align="left">t0 vs. HCs</td><td align="left">Parietal_Inf_L</td><td char="." align="char">61</td><td align="left">-54, -51,36</td><td char="." align="char">-4.907</td><td char="." align="char">315</td></tr><tr><td align="left"/><td align="left">t1 vs. HCs</td><td align="left">Frontal_Mid_R</td><td char="." align="char">8</td><td align="left">45,30,27</td><td char="." align="char">-3.8228</td><td char="." align="char">176</td></tr><tr><td align="left"/><td align="left">t1 vs. t0</td><td align="left">Insula_R</td><td char="." align="char">30</td><td align="left">51,3, -3</td><td char="." align="char">4.6003</td><td char="." align="char">84</td></tr></tbody></table><table-wrap-foot><p>Thresholds were set at a corrected p &lt; 0.01 corrected by FDR criterion. BA, Brodmann’s area; MNI, Montreal Neurological Institute; L, left; R, right; t0, lung cancer patients before chemotherapy; t1, lung cancer patients after chemotherapy; HCs, healthy controls</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Abnormal static functional connectivity between groups</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left">ROIs</th><th align="left">Group comparisons</th><th align="left">Brain region</th><th align="left">BA</th><th align="left">MNI Coordinatesx, y, z (mm)</th><th align="left">T score</th><th align="left">Voxels</th></tr></thead><tbody><tr><td align="left">R-DLPFC</td><td align="left">t0 vs. HCs</td><td align="left">Temporal_Sup_L</td><td char="." align="char">81</td><td align="left">-48, -21, 3</td><td char="." align="char">-4.2286</td><td char="." align="char">89</td></tr><tr><td align="left"/><td align="left"/><td align="left">Parietal_Inf_L</td><td char="." align="char">61</td><td align="left">-54, -51,36</td><td char="." align="char">-5.8758</td><td char="." align="char">315</td></tr><tr><td align="left"/><td align="left">t1 vs. HCs</td><td align="left">Frontal_Sup_R</td><td char="." align="char">6</td><td align="left">24, 57, -6</td><td char="." align="char">-4.4452</td><td char="." align="char">109</td></tr><tr><td align="left"/><td align="left"/><td align="left">Frontal_Sup_L</td><td char="." align="char">5</td><td align="left">-15, 60, -9</td><td char="." align="char">-4.1401</td><td char="." align="char">52</td></tr><tr><td align="left"/><td align="left"/><td align="left">Frontal_Mid_L</td><td char="." align="char">7</td><td align="left">-39,30,42</td><td char="." align="char">-4.689</td><td char="." align="char">145</td></tr><tr><td align="left"/><td align="left"/><td align="left">Cingulum_Mid_R</td><td char="." align="char">34</td><td align="left">9, -21,33</td><td char="." align="char">-4.1414</td><td char="." align="char">65</td></tr><tr><td align="left"/><td align="left">t1 vs. t0</td><td align="left">Frontal_Sup_L</td><td char="." align="char">3</td><td align="left">-18, 45, 22</td><td char="." align="char">-4.5187</td><td char="." align="char">85</td></tr><tr><td align="left"/><td align="left"/><td align="left">Frontal_Mid_R</td><td char="." align="char">8</td><td align="left">45, 33, 51</td><td char="." align="char">-3.7625</td><td char="." align="char">45</td></tr><tr><td align="left">L-DLPFC</td><td align="left">t0 vs. HCs</td><td align="left">Parietal_Inf_L</td><td char="." align="char">61</td><td align="left">-54, -51,36</td><td char="." align="char">-4.907</td><td char="." align="char">315</td></tr><tr><td align="left"/><td align="left">t1 vs. HCs</td><td align="left">Frontal_Mid_R</td><td char="." align="char">8</td><td align="left">45,30,27</td><td char="." align="char">-3.8228</td><td char="." align="char">176</td></tr><tr><td align="left"/><td align="left">t1 vs. t0</td><td align="left">Insula_R</td><td char="." align="char">30</td><td align="left">51,3, -3</td><td char="." align="char">4.6003</td><td char="." align="char">84</td></tr></tbody></table></div>Thresholds were set at a corrected p &lt; 0.01 corrected by FDR criterion. BA, Brodmann’s area; MNI, Montreal Neurological Institute; L, left; R, right; t0, lung cancer patients before chemotherapy; t1, lung cancer patients after chemotherapy; HCs, healthy controls</transformed-table></extracted-table><extracted-table><table-id>Tab3</table-id><table-label>Table 3</table-label><table-caption>Abnormal dynamic functional connectivity between groups</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table 3</label><caption><p>Abnormal dynamic functional connectivity between groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">ROIs</th><th align="left">Group comparisons</th><th align="left">Brain region</th><th align="left">BA</th><th align="left">MNI Coordinates<break/>x, y, z (mm)</th><th align="left">T score</th><th align="left">Voxels</th></tr></thead><tbody><tr><td align="left">R-DLPFC</td><td align="left">t0 vs. HCs</td><td align="left">Precuneus_L</td><td char="." align="left">67</td><td align="left">-6,-60,57</td><td char="." align="left">5.0394</td><td char="." align="left">77</td></tr><tr><td align="left"/><td align="left">t1 vs. HCs</td><td align="left">Parietal_Sup_R</td><td char="." align="left">60</td><td align="left">12,-45,63</td><td char="." align="left">-3.6612</td><td char="." align="left">43</td></tr><tr><td align="left"/><td align="left">t1 vs. t0</td><td align="left">Precuneus_L</td><td char="." align="left">67</td><td align="left">15,-60,60</td><td char="." align="left">-5.686</td><td char="." align="left">116</td></tr><tr><td align="left">L-DLPFC</td><td align="left">t0 vs. HCs</td><td align="left">Precuneus_L</td><td char="." align="left">67</td><td align="left">-6,-60,57</td><td char="." align="left">5.0394</td><td char="." align="left">77</td></tr><tr><td align="left"/><td align="left">t1 vs. HCs</td><td align="left">Frontal_Sup_L</td><td char="." align="left">3</td><td align="left">-18 -9,63</td><td char="." align="left">-4.2194</td><td char="." align="left">42</td></tr><tr><td align="left"/><td align="left">t1 vs. t0</td><td align="left">Temporal_Inf_L</td><td char="." align="left">89</td><td align="left">-57,-21,-27</td><td char="." align="left">-4.2989</td><td char="." align="left">43</td></tr><tr><td align="left"/><td align="left"/><td align="left">Frontal_Inf_R</td><td char="." align="left">16</td><td align="left">51,39,0</td><td char="." align="left">-4.4814</td><td char="." align="left">44</td></tr></tbody></table><table-wrap-foot><p>Thresholds were set at a corrected p &lt; 0.01 corrected by FDR criterion. BA, Brodmann’s area; MNI, Montreal Neurological Institute; L, left; R, right; t0, lung cancer patients before chemotherapy; t1, lung cancer patients after chemotherapy; HCs, healthy controls</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 3<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Abnormal dynamic functional connectivity between groups</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left">ROIs</th><th align="left">Group comparisons</th><th align="left">Brain region</th><th align="left">BA</th><th align="left">MNI Coordinatesx, y, z (mm)</th><th align="left">T score</th><th align="left">Voxels</th></tr></thead><tbody><tr><td align="left">R-DLPFC</td><td align="left">t0 vs. HCs</td><td align="left">Precuneus_L</td><td char="." align="left">67</td><td align="left">-6,-60,57</td><td char="." align="left">5.0394</td><td char="." align="left">77</td></tr><tr><td align="left"/><td align="left">t1 vs. HCs</td><td align="left">Parietal_Sup_R</td><td char="." align="left">60</td><td align="left">12,-45,63</td><td char="." align="left">-3.6612</td><td char="." align="left">43</td></tr><tr><td align="left"/><td align="left">t1 vs. t0</td><td align="left">Precuneus_L</td><td char="." align="left">67</td><td align="left">15,-60,60</td><td char="." align="left">-5.686</td><td char="." align="left">116</td></tr><tr><td align="left">L-DLPFC</td><td align="left">t0 vs. HCs</td><td align="left">Precuneus_L</td><td char="." align="left">67</td><td align="left">-6,-60,57</td><td char="." align="left">5.0394</td><td char="." align="left">77</td></tr><tr><td align="left"/><td align="left">t1 vs. HCs</td><td align="left">Frontal_Sup_L</td><td char="." align="left">3</td><td align="left">-18 -9,63</td><td char="." align="left">-4.2194</td><td char="." align="left">42</td></tr><tr><td align="left"/><td align="left">t1 vs. t0</td><td align="left">Temporal_Inf_L</td><td char="." align="left">89</td><td align="left">-57,-21,-27</td><td char="." align="left">-4.2989</td><td char="." align="left">43</td></tr><tr><td align="left"/><td align="left"/><td align="left">Frontal_Inf_R</td><td char="." align="left">16</td><td align="left">51,39,0</td><td char="." align="left">-4.4814</td><td char="." align="left">44</td></tr></tbody></table></div>Thresholds were set at a corrected p &lt; 0.01 corrected by FDR criterion. BA, Brodmann’s area; MNI, Montreal Neurological Institute; L, left; R, right; t0, lung cancer patients before chemotherapy; t1, lung cancer patients after chemotherapy; HCs, healthy controls</transformed-table></extracted-table><extracted-table><table-id>Tab4</table-id><table-label>Table 4</table-label><table-caption>Abnormal dynamic functional connectivity of R-DLPFC at different states between groups</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab4"><label>Table 4</label><caption><p>Abnormal dynamic functional connectivity of R-DLPFC at different states between groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">States</th><th align="left">Group comparisons</th><th align="left">Brain region</th><th align="left">BA</th><th align="left">MNI Coordinates<break/>x, y, z (mm)</th><th align="left">T score</th><th align="left">Voxels</th></tr></thead><tbody><tr><td align="left">State 1</td><td align="left">t0 vs. HCs</td><td align="left">Fusiform_L</td><td char="." align="left">55</td><td char="−" align="left">-42,-57,-18</td><td char="." align="left">-2.8578</td><td char="." align="left">45</td></tr><tr><td align="left"/><td align="left">t1 vs. HCs</td><td align="left">Cingulum_Post_L</td><td char="." align="left">35</td><td char="−" align="left">-6,-39,12</td><td char="." align="left">3.2144</td><td char="." align="left">42</td></tr><tr><td align="left"/><td align="left">t1 vs. t0</td><td align="left">Frontal_Sup_L</td><td char="." align="left">3</td><td align="left">-48,36,21</td><td char="." align="left">-4.8199</td><td char="." align="left">58</td></tr><tr><td align="left">State 2</td><td align="left">t0 vs. HCs</td><td align="left">Insula_L</td><td char="." align="left">30</td><td align="left">-45,18,0</td><td char="." align="left">-3.5169</td><td char="." align="left">62</td></tr><tr><td align="left"/><td align="left"/><td align="left">Frontal_Mid_L</td><td char="." align="left">7</td><td align="left">-33,54,21</td><td char="." align="left">-3.2704</td><td char="." align="left">106</td></tr><tr><td align="left"/><td align="left">t1 vs. HCs</td><td align="left">Thalamus_R</td><td char="." align="left">78</td><td char="−" align="left">12,-21,9</td><td char="." align="left">-3.4867</td><td char="." align="left">66</td></tr><tr><td align="left"/><td align="left">t1 vs. t0</td><td align="left"><p>Insula_L</p><p>Frontal_Mid_L</p></td><td char="." align="left"><p>29</p><p>7</p></td><td char="−" align="left"><p>-30,24,-6</p><p>-42,42,24</p></td><td char="." align="left"><p>3.9534</p><p>4.4502</p></td><td char="." align="left"><p>61</p><p>193</p></td></tr></tbody></table><table-wrap-foot><p>Thresholds were set at a corrected p &lt; 0.01 corrected by FDR criterion. BA, Brodmann’s area; MNI, Montreal Neurological Institute; L, left; R, right; t0, lung cancer patients before chemotherapy; t1, lung cancer patients after chemotherapy; HCs, healthy controls</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 4<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Abnormal dynamic functional connectivity of R-DLPFC at different states between groups</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left">States</th><th align="left">Group comparisons</th><th align="left">Brain region</th><th align="left">BA</th><th align="left">MNI Coordinatesx, y, z (mm)</th><th align="left">T score</th><th align="left">Voxels</th></tr></thead><tbody><tr><td align="left">State 1</td><td align="left">t0 vs. HCs</td><td align="left">Fusiform_L</td><td char="." align="left">55</td><td char="−" align="left">-42,-57,-18</td><td char="." align="left">-2.8578</td><td char="." align="left">45</td></tr><tr><td align="left"/><td align="left">t1 vs. HCs</td><td align="left">Cingulum_Post_L</td><td char="." align="left">35</td><td char="−" align="left">-6,-39,12</td><td char="." align="left">3.2144</td><td char="." align="left">42</td></tr><tr><td align="left"/><td align="left">t1 vs. t0</td><td align="left">Frontal_Sup_L</td><td char="." align="left">3</td><td align="left">-48,36,21</td><td char="." align="left">-4.8199</td><td char="." align="left">58</td></tr><tr><td align="left">State 2</td><td align="left">t0 vs. HCs</td><td align="left">Insula_L</td><td char="." align="left">30</td><td align="left">-45,18,0</td><td char="." align="left">-3.5169</td><td char="." align="left">62</td></tr><tr><td align="left"/><td align="left"/><td align="left">Frontal_Mid_L</td><td char="." align="left">7</td><td align="left">-33,54,21</td><td char="." align="left">-3.2704</td><td char="." align="left">106</td></tr><tr><td align="left"/><td align="left">t1 vs. HCs</td><td align="left">Thalamus_R</td><td char="." align="left">78</td><td char="−" align="left">12,-21,9</td><td char="." align="left">-3.4867</td><td char="." align="left">66</td></tr><tr><td align="left"/><td align="left">t1 vs. t0</td><td align="left">Insula_LFrontal_Mid_L</td><td char="." align="left">297</td><td char="−" align="left">-30,24,-6-42,42,24</td><td char="." align="left">3.95344.4502</td><td char="." align="left">61193</td></tr></tbody></table></div>Thresholds were set at a corrected p &lt; 0.01 corrected by FDR criterion. BA, Brodmann’s area; MNI, Montreal Neurological Institute; L, left; R, right; t0, lung cancer patients before chemotherapy; t1, lung cancer patients after chemotherapy; HCs, healthy controls</transformed-table></extracted-table><extracted-table><table-id>Tab5</table-id><table-label>Table 5</table-label><table-caption>Abnormal dynamic functional connectivity of L-DLPFC at different states between groups</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab5"><label>Table 5</label><caption><p>Abnormal dynamic functional connectivity of L-DLPFC at different states between groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">State</th><th align="left">Group comparisons</th><th align="left">Brain region</th><th align="left">BA</th><th align="left">MNI Coordinates<break/>x, y, z (mm)</th><th align="left">T score</th><th align="left">Voxels</th></tr></thead><tbody><tr><td align="left">State 1</td><td align="left">t0 vs. HCs</td><td align="left">Frontal_Inf _L</td><td char="." align="left">15</td><td align="left">-45,18,3</td><td char="." align="left">-3.5752</td><td char="." align="left">85</td></tr><tr><td align="left"/><td align="left">t1 vs. HCs</td><td align="left">Frontal_Inf _L</td><td char="." align="left">13</td><td align="left">-54,24,9</td><td char="." align="left">-2.6263</td><td char="." align="left">50</td></tr><tr><td align="left"/><td align="left">t1 vs. t0</td><td align="left">Frontal_Sup _R</td><td char="." align="left">6</td><td align="left">24,69,-3</td><td char="." align="left">-3.9716</td><td char="." align="left">71</td></tr><tr><td align="left">State 2</td><td align="left">t0 vs. HCs</td><td align="left">Cingulum_Mid_R</td><td char="." align="left">34</td><td align="left">12,-21,45</td><td char="." align="left">-3.6457</td><td char="." align="left">54</td></tr><tr><td align="left"/><td align="left">t1 vs. t0</td><td align="left">Frontal_Mid_R</td><td char="." align="left">8</td><td align="left">39,27,36</td><td char="." align="left">-4.1514</td><td char="." align="left">45</td></tr><tr><td align="left">State 3</td><td align="left">t1 vs. HCs</td><td align="left">Cingulum_Mid_R</td><td char="." align="left">34</td><td align="left">9,24,30</td><td char="." align="left">3.5843</td><td char="." align="left">56</td></tr><tr><td align="left"/><td align="left">t1 vs. t0</td><td align="left">Cingulum_Mid_R</td><td char="." align="left">34</td><td align="left">12,-24,27</td><td char="." align="left">3.6361</td><td char="." align="left">60</td></tr></tbody></table><table-wrap-foot><p>Thresholds were set at a corrected p &lt; 0.01 corrected by FDR criterion. BA, Brodmann’s area; MNI, Montreal Neurological Institute; L, left; R, right; t0, lung cancer patients before chemotherapy; t1, lung cancer patients after chemotherapy; HCs, healthy controls</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 5<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Abnormal dynamic functional connectivity of L-DLPFC at different states between groups</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th align="left">State</th><th align="left">Group comparisons</th><th align="left">Brain region</th><th align="left">BA</th><th align="left">MNI Coordinatesx, y, z (mm)</th><th align="left">T score</th><th align="left">Voxels</th></tr></thead><tbody><tr><td align="left">State 1</td><td align="left">t0 vs. HCs</td><td align="left">Frontal_Inf _L</td><td char="." align="left">15</td><td align="left">-45,18,3</td><td char="." align="left">-3.5752</td><td char="." align="left">85</td></tr><tr><td align="left"/><td align="left">t1 vs. HCs</td><td align="left">Frontal_Inf _L</td><td char="." align="left">13</td><td align="left">-54,24,9</td><td char="." align="left">-2.6263</td><td char="." align="left">50</td></tr><tr><td align="left"/><td align="left">t1 vs. t0</td><td align="left">Frontal_Sup _R</td><td char="." align="left">6</td><td align="left">24,69,-3</td><td char="." align="left">-3.9716</td><td char="." align="left">71</td></tr><tr><td align="left">State 2</td><td align="left">t0 vs. HCs</td><td align="left">Cingulum_Mid_R</td><td char="." align="left">34</td><td align="left">12,-21,45</td><td char="." align="left">-3.6457</td><td char="." align="left">54</td></tr><tr><td align="left"/><td align="left">t1 vs. t0</td><td align="left">Frontal_Mid_R</td><td char="." align="left">8</td><td align="left">39,27,36</td><td char="." align="left">-4.1514</td><td char="." align="left">45</td></tr><tr><td align="left">State 3</td><td align="left">t1 vs. HCs</td><td align="left">Cingulum_Mid_R</td><td char="." align="left">34</td><td align="left">9,24,30</td><td char="." align="left">3.5843</td><td char="." align="left">56</td></tr><tr><td align="left"/><td align="left">t1 vs. t0</td><td align="left">Cingulum_Mid_R</td><td char="." align="left">34</td><td align="left">12,-24,27</td><td char="." align="left">3.6361</td><td char="." align="left">60</td></tr></tbody></table></div>Thresholds were set at a corrected p &lt; 0.01 corrected by FDR criterion. BA, Brodmann’s area; MNI, Montreal Neurological Institute; L, left; R, right; t0, lung cancer patients before chemotherapy; t1, lung cancer patients after chemotherapy; HCs, healthy controls</transformed-table></extracted-table></extracted-tables-set>